FDA reviewers expressed skepticism about widening the use of Eli Lilly and Co.'s Cymbalta, saying the statistical methodology for a clinical study in patients with chronic pain appears "problematic." An advisory panel is scheduled Thursday to decide whether to endorse Cymbalta for approval as a chronic pain treatment.

Full Story:

Related Summaries